DR Horton Net Income TTM
| DHI Stock | USD 147.63 1.66 1.14% |
| = | 3.59 B |
DR Horton's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Net Income | = | (Rev + Gain) | - | (Exp + Loss) |
Current DR Horton Net Income TTM | 3.59 B |
Core metrics such as Net Income TTM form the backbone of any value-based review of DR Horton. When the market price drops below the estimated true value, it may offer a research lead for value investors. Cross-checking multiple valuation measures reduces the risk of drawing conclusions from one metric's blind spots. DR Horton currently trades at a P/E of 5.10, which provides additional valuation context. This analysis is offered for research and learning purposes. A price-to-book ratio of 1.76 helps frame the market's assessment of DR Horton's asset base.
Net Income TTM Driver Correlations
Mapping Net Income TTM against DR Horton's other financial drivers surfaces the strongest account-level relationships. Clusters of correlated accounts often correspond to distinct business segments or cost centers at DR Horton.
Click cells to compare fundamentals
| Competition |
DHI Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income | 0.00 |
Fundamental Drivers Relationships
Net Income stood at 4.33 billion as of December 31, 2025. Related reported metrics: Net Income From Continuing Ops at 2.31 billion as of December 31, 2025; Net Income Per Share at 0.01 as of December 31, 2025.
Net Income TTM Peer Comparison
Stock peer comparison using Net Income TTM is a widely accepted framework for evaluating DR Horton within its group. Investors who find DR Horton's Net Income TTM more favorable than peers may view DR Horton as attractively valued. Peer dispersion in Net Income TTM across the group provides context for evaluating DR Horton's competitive positioning.DR Horton is currently under evaluation for net income ttm among direct rivals.
Important Fundamentals
| Return On Equity TTM | 0.13 | |||
| Return On Asset TTM | 0.073 | |||
| Profit Margin TTM | 0.0951 | |||
| Operating Margin TTM | 0.11 | |||
| Current Valuation | 46.25 B | |||
| Shares Outstanding | 283.58 M | |||
| Shares Owned By Insiders | 11.57 % | |||
| Shares Owned By Institutions | 89.69 % | |||
| Number Of Shares Shorted | 15.42 M | |||
| Price To Earnings TTM | 5.10 X | |||
| Price To Book TTM | 1.76 X | |||
| Price To Sales TTM | 1.26 X | |||
| Revenue TTM | 34.25 B | |||
| Gross Profit TTM | 7.2 B | |||
| EBITDA TTM | 4.84 B | |||
| Net Income TTM | 3.59 B | |||
| Cash And Equivalents TTM | 2.99 B | |||
| Cash Per Share TTM | 7.08 X | |||
| Total Debt TTM | 6.03 B | |||
| Debt To Equity TTM | 0.31 % | |||
| Current Ratio TTM | 5.24 X | |||
| Book Value Per Share TTM | 82.92 X | |||
| Cash Flow From Operations TTM | 3.42 B | |||
| Short Ratio TTM | 5.55 X | |||
| Earnings Per Share | 10.64 X | |||
| Price To Earnings To Growth | 1.37 X | |||
| Target Price | 165.29 | |||
| Number Of Employees | 14.34 K | |||
| Trailing Beta | 1.41 | |||
| Market Capitalization TTM | 41.86 B | |||
| Total Asset TTM | 35.47 B | |||
| Retained Earnings TTM | 31.04 B | |||
| Working Capital TTM | 32.18 B | |||
| Current Asset TTM | 9.78 B | |||
| Current Liabilities TTM | 849.2 M | |||
| Annual Yield | 0.0122 | |||
| Five Year Return | 1.11 % | |||
| Net Asset | 35.47 B | |||
| Last Dividend Paid | 1.7 |
Financial Metrics, Fundamentals & Methodology
DR Horton's operating framework helps explain margin behavior, earnings persistence, and funding capacity. Debt exposure shapes how much financial pressure DR Horton could face in weaker periods. Latest reported fundamentals for DR Horton include revenue of 34.25 billion, positive EPS of 10.64, operating margin of 11.26%, current ratio of 5.24 as of the latest reporting period.
DR Horton metrics are compiled from periodic company reporting and market reference feeds and normalized before display. Analyst projections are included when active coverage applies. Accounting-line values follow GAAP or IFRS structures as published in issuer filings.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board